Navigation Links
Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
Date:6/17/2010

CALGARY, June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.

Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This news release contains forward-looking statements,
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... medical device industries, has announced a laboratory and office ... consolidated its histology and tissue analysis operations from separate ... north of Denver. The new addresses are: , ... 100, Westminster, CO 80021 , Tissue Image Analysis Lab, ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... Boca Raton, FL (PRWEB) August 27, 2014 ... that are applied through the use of a handheld ... consumers across the United States. , The brand ... care unit. BIOEQUA researchers were surprised to learn that ... to be made extremely small and delivered directly to ...
(Date:8/27/2014)... Remcom announces an update to XFdtd® ... the biomedical industry. The central biomedical addition in ... to the Bio-Pro version of the software. XFdtd ... calculate the biological effects of electromagnetic fields. In ... versions to expand engineers’ post-processing options. , The Biological ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... ,Kidney-Friendly, Recipes, HOUSTON, Dec. 7 Celebrity ... SHPGY ), the global biopharmaceutical,company, today announced that ... the Doubletree Hotel Houston Downtown from 1-3 PM,tomorrow, ... kidney,disease (CKD) and their families., During the ...
... Tutogen Medical, Inc.,(Amex: TTG ), a leading manufacturer ... animal (xenograft) tissue, will report,financial results for the fourth ... December 10, 2007 at 4:30 p.m. ET., Interested ... or,(706) 679-5064 or by accessing the web cast at, ...
... Group in North America with this Elevated Partner ... ... an Oracle System,Integrator, today announced it has achieved Oracle Certified Advantage,Partner status ... the highest level in the Oracle PartnerNetwork -- BIAS had,to demonstrate superior ...
Cached Biology Technology:Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 2Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 3Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 4Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 5Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 6Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease 7Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 3
(Date:8/27/2014)... disease that exists as five strains, none of which ... is the Sudan ebolavirus (SUDV). Although not the strain ... even as recently as 2012. In a new study ... researchers now report a possible therapy that could someday ... Sachdev Sidhu, Jonathan Lai and colleagues explain that about ...
(Date:8/27/2014)... basic research, a growing focus on translating discoveries ... have earned the Herbert Irving Comprehensive Cancer Center ... NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center ... The grant renews the center,s status as one ... New York City and one of only three ...
(Date:8/27/2014)... shown that excessive iron is closely associated ... studies from Chunyan Guo and co-workers from ... that baicalin prevented iron accumulation after substantia ... expression, and increased ferroportin 1 expression in ... rats. However, the relationship between iron concentration ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... the brain, cells called neurons go through a cycle ... Fernando Nottebohm, Ph.D., shows that these replaceable neurons share ... people with diseases such as Alzheimer's and Parkinson's: both ... , "It would be ironic if the shortfall in ...
... the vertebrate embryo - the establishment of a back ... - turns out to be so important that the ... it happens properly. , The discovery, reported this month ... University of California, Berkeley, finally explains an 80-year-old observation ...
... a major domain of telomerase, the enzyme that helps maintain ... that act as protective caps -- allowing DNA ends to ... the first major piece of telomerase for which the structure ... and this work ultimately may lead to targets for drug ...
Cached Biology News:One gene links newborn neurons with those that die in diseases such as Alzheimer's 2One gene links newborn neurons with those that die in diseases such as Alzheimer's 3One gene links newborn neurons with those that die in diseases such as Alzheimer's 4Scientists discover that three overlapping signals in embryo help get the backbone right 2Scientists discover that three overlapping signals in embryo help get the backbone right 3Scientists discover that three overlapping signals in embryo help get the backbone right 4Scientists discover that three overlapping signals in embryo help get the backbone right 5Biochemists report discovery of structure of major piece of telomerase; implications for cancer 2Biochemists report discovery of structure of major piece of telomerase; implications for cancer 3
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... The RiboGreen RNA Quantitation Kit is ... systems for the quantitation of RNA ... approximately 1000-fold more sensitive than absorbance ... can be detected with fluorescence microplate ...
... GenoStat Inducible Expression System provides tightly regulated ... cells and is capable of repeated on/off ... mediated by the highly specific interaction between ... nuclear receptor complex. Gene expression levels are ...
Biology Products: